KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardlytics (CDLX) Asset Writedowns and Impairment (2017 - 2025)

Cardlytics (CDLX) has disclosed Asset Writedowns and Impairment for 9 consecutive years, with $352000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Asset Writedowns and Impairment fell 83.44% year-over-year to $352000.0, compared with a TTM value of $2.1 million through Dec 2025, down 98.45%, and an annual FY2025 reading of $2.1 million, down 65.05% over the prior year.
  • Asset Writedowns and Impairment was $352000.0 for Q4 2025 at Cardlytics, up from -$51000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $131.6 million in Q3 2024 and bottomed at -$1.4 million in Q4 2021.
  • Average Asset Writedowns and Impairment over 5 years is $7.2 million, with a median of $597000.0 recorded in 2023.
  • The sharpest move saw Asset Writedowns and Impairment tumbled 171.1% in 2023, then skyrocketed 32074.82% in 2024.
  • Year by year, Asset Writedowns and Impairment stood at -$1.4 million in 2021, then surged by 200.69% to $1.4 million in 2022, then plummeted by 62.0% to $551000.0 in 2023, then skyrocketed by 285.84% to $2.1 million in 2024, then tumbled by 83.44% to $352000.0 in 2025.
  • Business Quant data shows Asset Writedowns and Impairment for CDLX at $352000.0 in Q4 2025, -$51000.0 in Q3 2025, and $1.2 million in Q2 2025.